First Tracks Biotherapeutics, Inc. (TRAX) Revenue, Earnings & Financial Statements
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
First Tracks Biotherapeutics, Inc. most recently reported annual revenue of $0, a net loss of $166.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
First Tracks Biotherapeutics, Inc.: net profit was positive in 0 of 3 reported years; the most recent year shows a net loss of $166.0M.
Income Statement — 3 Years (USD millions)
Quarterly Results — Last 5 Quarters (USD millions)
Over the 3 years reported for First Tracks Biotherapeutics, Inc., borrowings decreased from $18.0M in 2023 to $14.0M in 2025, cash stood at $238.0M in the latest year, shareholders' equity was $288.0M, current assets covered current liabilities 10.19 times.
Balance Sheet — 3 Years (USD millions)
For First Tracks Biotherapeutics, Inc., operating cash flow was positive in 0 of 3 reported years; free cash flow in the latest year was negative at $143.0M; free cash flow was positive in 0 of 3 years.
Cash Flow Statement — 3 Years (USD millions)
Valuation & Return Ratios
First Tracks Biotherapeutics, Inc. (TRAX) financials — frequently asked questions
What is First Tracks Biotherapeutics, Inc.'s annual revenue?
First Tracks Biotherapeutics, Inc. (TRAX) reported annual revenue of $0 in its most recent fiscal year.
What is First Tracks Biotherapeutics, Inc.'s net profit?
First Tracks Biotherapeutics, Inc. (TRAX) reported a net loss of $166.0M in its most recent fiscal year.
What is TRAX EV/EBITDA?
First Tracks Biotherapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -2.47. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.